Ligand Pharmaceuticals LGND Other intangible assets—net
Other intangible assets—net at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's other intangible assets—net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's other intangible assets—net?
- Ligand Pharmaceuticals (LGND) reported other intangible assets—net of $217.34M in Q1 2026.
- How has Ligand Pharmaceuticals's other intangible assets—net changed year-over-year?
- Ligand Pharmaceuticals's other intangible assets—net decreased by 15.9% year-over-year, from $258.39M to $217.34M.
- What is the long-term trend for Ligand Pharmaceuticals's other intangible assets—net?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's other intangible assets—net has grown at a -17.7% compound annual growth rate (CAGR), from $595.33M to $225.44M.
- What does other intangible assets—net mean?
- This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.